On March 12, 2024, TC BioPharm (Holdings) PLC, a Scotland-based biopharmaceutical company, reported the issuance of 623,750 American Depositary Shares (ADSs) representing 12,475,000 ordinary shares. This issuance was the result of the exercise of outstanding warrants that were initially issued on August 30, 2023, and disclosed in a Report of Foreign Private Issuer filed with the SEC the following day. The transaction generated gross cash proceeds of approximately £986,398 (around $1,263,000) for TC BioPharm. The ADSs were issued under the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act. The company, which is registered with the United States Securities and Exchange Commission and listed on The Nasdaq Stock Market LLC, is identified as an emerging growth company.

On March 12, 2024, TC BioPharm (Holdings) PLC, a Scotland-based biopharmaceutical company, reported the issuance of 623,750 American Depositary Shares (ADSs) representing 12,475,000 ordinary shares. This issuance was the result of the exercise of outstanding warrants that were initially issued on August 30, 2023, and disclosed in a Report of Foreign Private Issuer filed with the SEC the following day. The transaction generated gross cash proceeds of approximately £986,398 (around $1,263,000) for TC BioPharm. The ADSs were issued under the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act. The company, which is registered with the United States Securities and Exchange Commission and listed on The Nasdaq Stock Market LLC, is identified as an emerging growth company.